CoChat

The DOI matches its Crossref record; 41 of the 51 references it cites were found in a registry or an index.

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist

Open access

Abstract

Significance: Glucagon-like peptide-1 receptor agonists have become established as a leading class of diabetes medications. However, these peptide-based drugs are administered by subcutaneous injection or, in one case, by a complex oral dosing regimen. We now report the discovery of LY3502970, a potent and selective small-molecule GLP-1R agonist. LY3502970 exhibits preclinical pharmacology equivalent to a marketed injectable GLP-1R agonist and possesses pharmacokinetic properties compatible with oral dosing in humans. Cryoelectron microscopy (cryo-EM) studies reveal an ECD-driven receptor binding mode for LY3502970 that provides a favorable pharmacological profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2014879117

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Pharmacology and structural analysis of LY3502970 in complex with GLP-1R/GsiN18/Nb35/scFv16. (A) Chemical structure of LY3502970 (molecular weight: 882.96, formula: C48H48F2N10O5). Moieties that are discussed in the cryo-EM structural analysis are highlighted in colored boxes. (B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined. Human GLP-1R density-dependent pharmacology of ligands was quantified by measuring the potency and efficacy for cAMP accumulation at increasing levels of receptor density (high, medium, low). Functional potency and efficacy for β-arrestin recruitment using enzyme fragment complementation was determined. Representative concentration response curves are presented. Summarized data with statistics are presented in SI Appendix, Table S1. (D) LY3502970 does not stimulate cAMP accumulation in HEK293 cells expressing the mouse GLP-1R. Data are presented as the mean ± SD of three independent experiments. (E) Mice expressing the human GLP-1R (n = 5 mice/group) were fasted overnight and orally administered vehicle or LY3502970 (0.1 to 10 mg/kg). Five hours later, animals received an intraperitoneal (i.p.) injection of glucose (2 g/kg). As a control group, one cohort was dosed with a s.c. injection of exenatide (1 nmol/kg) 1 h prior to receiving the i.p. glucose. For all mice, the circulating concentration of glucose over various time points was measured using glucometers. Each dose of LY3502970 reduced the glucose excursion AUC versus vehicle (P < 0.05; one-way ANOVA followed by the Dunnett’s test). (F) Similar studies were perfumed in Glp1r null mice. In these experiments, vehicle or LY3502970 (10 mg/kg) was administered orally and exenatide (1 nmol/kg) or gastric inhibitory polypeptide, (GIP) (30 nmol/kg) was dosed via s.c. injection. Data are mean ± SEM (n = 4 to 5 mice/group). (G) Overall structure of GLP-1R/LY3502970/GsiN18/Nb35/scFv16. Each subunit or ligand is shown with a different color (GLP-1R: green for 7TM and blue green for ECD; LY3502970: magenta; GsαiN18: bright blue; Gβ: light orange; Gγ: green cyan; scFv16: salmon; Nb35: violet). (H) Surface representation of LY3502970 binding pocket. The 7TM domain of GLP-1R is colored in green, while ECD is colored blue green. LY3502970 is shown by spheres. (I) LY3502970 interacts with residues from both the ECD and 7TM of GLP-1R. LY3502970, and its interaction residues are shown by sticks. Hydrogen bonds are indicated by dashed lines.
Fig. 1. Pharmacology and structural analysis of LY3502970 in complex with GLP-1R/GsiN18/Nb35/scFv16. (A) Chemical structure of LY3502970 (molecular weight: 882.96, formula: C48H48F2N10O5). Moieties that are discussed in the cryo-EM structural analysis are highlighted in colored boxes. (B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined. Human GLP-1R density-dependent pharmacology of ligands was quantified by measuring the potency and efficacy for cAMP accumulation at increasing levels of receptor density (high, medium, low). Functional potency and efficacy for β-arrestin recruitment using enzyme fragment complementation was determined. Representative concentration response curves are presented. Summarized data with statistics are presented in SI Appendix, Table S1. (D) LY3502970 does not stimulate cAMP accumulation in HEK293 cells expressing the mouse GLP-1R. Data are presented as the mean ± SD of three independent experiments. (E) Mice expressing the human GLP-1R (n = 5 mice/group) were fasted overnight and orally administered vehicle or LY3502970 (0.1 to 10 mg/kg). Five hours later, animals received an intraperitoneal (i.p.) injection of glucose (2 g/kg). As a control group, one cohort was dosed with a s.c. injection of exenatide (1 nmol/kg) 1 h prior to receiving the i.p. glucose. For all mice, the circulating concentration of glucose over various time points was measured using glucometers. Each dose of LY3502970 reduced the glucose excursion AUC versus vehicle (P < 0.05; one-way ANOVA followed by the Dunnett’s test). (F) Similar studies were perfumed in Glp1r null mice. In these experiments, vehicle or LY3502970 (10 mg/kg) was administered orally and exenatide (1 nmol/kg) or gastric inhibitory polypeptide, (GIP) (30 nmol/kg) was dosed via s.c. injection. Data are mean ± SEM (n = 4 to 5 mice/group). (G) Overall structure of GLP-1R/LY3502970/GsiN18/Nb35/scFv16. Each subunit or ligand is shown with a different color (GLP-1R: green for 7TM and blue green for ECD; LY3502970: magenta; GsαiN18: bright blue; Gβ: light orange; Gγ: green cyan; scFv16: salmon; Nb35: violet). (H) Surface representation of LY3502970 binding pocket. The 7TM domain of GLP-1R is colored in green, while ECD is colored blue green. LY3502970 is shown by spheres. (I) LY3502970 interacts with residues from both the ECD and 7TM of GLP-1R. LY3502970, and its interaction residues are shown by sticks. Hydrogen bonds are indicated by dashed lines.CC BY · PubMed Central
Fig. 2. Trp33ECD mediates key interaction with LY3502970 and the surrounding region. (A) Amino acid sequence comparison of the ECD regions for GLP-1Rs of different species. (B) LY3502970 increases cAMP accumulation in HEK293 cells expressing a chimeric form of the mouse GLP-1R (domains shown in green) where the N-terminal 142 residues have been replaced by the corresponding region of the human GLP-1R (domains shown in blue). (C) Mutation of Ser33ECD to Trp33ECD in the mouse GLP-1R enables LY3502970 to stimulate receptor-induced cAMP accumulation, while the reciprocal mutation (D) in the human GLP-1R abolishes compound function. The chimera and mutant data are presented as the mean ± SD of three independent experiments. (E) Trp33ECD interacts with LY3502970 and residues on TM2, ECL1, and ECL2. Residues and ligands are shown by sticks except Trp33ECD, which is also shown by spheres. Hydrogen bonds are indicated by dashed lines. (F) GLP-1R ECD orientation in the LY3502970 bound structure stabilized by aromatic interactions with ECL1. (G) The unique ECD orientation of ECD in the LY3502970 bound structure as a result of the unique Trp33ECD position. The structures of GLP-1R bound to LY3502970 (7TM in green, ECD in blue green, LY3502970 in magenta), GLP-1 (yellow, PDB ID code 6VCB), and peptide 5 (gray, PDB ID code 5NX2) are aligned. Trp33ECD is shown by a stick. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J) are not shown here, but their ECD orientations are very similar to GLP-1 bound structure 6VCB in yellow. (H and I) Competitive inhibition of [125I]GLP-1(7-36) binding to membranes isolated from cells expressing the human GLP-1R (H) or human W33S GLP-1R (I). Data are represented as the mean ± SD of three independent experiments.
Fig. 2. Trp33ECD mediates key interaction with LY3502970 and the surrounding region. (A) Amino acid sequence comparison of the ECD regions for GLP-1Rs of different species. (B) LY3502970 increases cAMP accumulation in HEK293 cells expressing a chimeric form of the mouse GLP-1R (domains shown in green) where the N-terminal 142 residues have been replaced by the corresponding region of the human GLP-1R (domains shown in blue). (C) Mutation of Ser33ECD to Trp33ECD in the mouse GLP-1R enables LY3502970 to stimulate receptor-induced cAMP accumulation, while the reciprocal mutation (D) in the human GLP-1R abolishes compound function. The chimera and mutant data are presented as the mean ± SD of three independent experiments. (E) Trp33ECD interacts with LY3502970 and residues on TM2, ECL1, and ECL2. Residues and ligands are shown by sticks except Trp33ECD, which is also shown by spheres. Hydrogen bonds are indicated by dashed lines. (F) GLP-1R ECD orientation in the LY3502970 bound structure stabilized by aromatic interactions with ECL1. (G) The unique ECD orientation of ECD in the LY3502970 bound structure as a result of the unique Trp33ECD position. The structures of GLP-1R bound to LY3502970 (7TM in green, ECD in blue green, LY3502970 in magenta), GLP-1 (yellow, PDB ID code 6VCB), and peptide 5 (gray, PDB ID code 5NX2) are aligned. Trp33ECD is shown by a stick. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J) are not shown here, but their ECD orientations are very similar to GLP-1 bound structure 6VCB in yellow. (H and I) Competitive inhibition of [125I]GLP-1(7-36) binding to membranes isolated from cells expressing the human GLP-1R (H) or human W33S GLP-1R (I). Data are represented as the mean ± SD of three independent experiments.CC BY · PubMed Central
Fig. 3. LY3502970 binding and the conformation of TM1, TM2, and TM7 of the GLP-1R. (A) LY3502970 (magenta) interactions with TM1, TM2, and TM7 of GLP-1R (green). Residues and ligands are shown by sticks. (B) TM1, TM7, and ECL3 of the inactive state structure of GLP-1R (salmon, PDB ID code 6LN2) need to shift to interact with LY3502970 (magenta sphere). (C) Unique conformation of TM1 and TM2 to accommodate LY3502970. The structures of GLP-1R bound to LY3502970, GLP-1 (yellow, PDB ID code 6VCB), and TT-OAD2 (cyan, PDB ID code 6ORV) are aligned. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J; peptide 5, PDB ID code 5NX2) are not shown here, but their TM1, TM2, and TM3 conformations are very similar to GLP-1 bound structure 6VCB in yellow.
Fig. 3. LY3502970 binding and the conformation of TM1, TM2, and TM7 of the GLP-1R. (A) LY3502970 (magenta) interactions with TM1, TM2, and TM7 of GLP-1R (green). Residues and ligands are shown by sticks. (B) TM1, TM7, and ECL3 of the inactive state structure of GLP-1R (salmon, PDB ID code 6LN2) need to shift to interact with LY3502970 (magenta sphere). (C) Unique conformation of TM1 and TM2 to accommodate LY3502970. The structures of GLP-1R bound to LY3502970, GLP-1 (yellow, PDB ID code 6VCB), and TT-OAD2 (cyan, PDB ID code 6ORV) are aligned. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J; peptide 5, PDB ID code 5NX2) are not shown here, but their TM1, TM2, and TM3 conformations are very similar to GLP-1 bound structure 6VCB in yellow.CC BY · PubMed Central
Fig. 4. Structures of GLP-1R bound to agonists with different signaling profiles shed light on the structural basis for partial agonism and biased signaling. (A) Structures of the GLP-1R bound to LY3502970 (7TM in green, LY3502970 shown by magenta spheres), native GLP-1 (receptor in yellow, GLP-1 in beige, PDB ID code 6VCB), ExP5 (receptor in orange, ExP5 in pink, PDB ID code 6B3J), or TT-OAD2 (receptor in cyan, TT-OAD2 in blue, PDB ID code 6ORV) are aligned and shown from an identical view. Critical residues are shown by sticks. Hydrogen bonds are indicated by dashed lines. (B) The structure of GLP-1R bound to LY3502970 is aligned with GLP-1R bound to ExP5 and TT-OAD2 (Upper) and GLP-1 (Lower).
Fig. 4. Structures of GLP-1R bound to agonists with different signaling profiles shed light on the structural basis for partial agonism and biased signaling. (A) Structures of the GLP-1R bound to LY3502970 (7TM in green, LY3502970 shown by magenta spheres), native GLP-1 (receptor in yellow, GLP-1 in beige, PDB ID code 6VCB), ExP5 (receptor in orange, ExP5 in pink, PDB ID code 6B3J), or TT-OAD2 (receptor in cyan, TT-OAD2 in blue, PDB ID code 6ORV) are aligned and shown from an identical view. Critical residues are shown by sticks. Hydrogen bonds are indicated by dashed lines. (B) The structure of GLP-1R bound to LY3502970 is aligned with GLP-1R bound to ExP5 and TT-OAD2 (Upper) and GLP-1 (Lower).CC BY · PubMed Central
Fig. 5. LY3502970 enhances glucose-stimulated insulin secretion and reduces food consumption in cynomolgus monkeys. (B–E) Effects of LY3502970 in IVGTT experiments. (A) Schematic diagram of the IVGTT procedure in anesthetized cynomolgus monkeys. Dosing of LY3502970 or exenatide was performed by manual bolus injection, followed by continuous infusion for 80 min. Forty minutes after initiating dosing of vehicle or the drug, glucose was administered intravenously. (B and C) Effect of LY3502970 (B) or exenatide (C) on blood glucose levels. (D and E) Effect of LY3502970 (D) or exenatide (E) on serum insulin levels. Data are represented as the mean ± SEM (n = 7). Significantly different from vehicle 1 or vehicle 2 by Dunnett’s test at *P < 0.025 and **P < 0.005 (one tailed), respectively. Vehicle 1: PEG400/PG/Gly NaOH buffer (pH 9), vehicle 2: 0.05% Tween80 PBS. (F and G) Mean food consumption following administration of LY3502970 (F) or exenatide (G). Cynomolgus monkeys were administered LY3502970, exenatide, or vehicle once daily for 5 d with a 2 d recovery period using an 8 × 5 cross-over design. Food consumption during the 90 min period after feeding was measured. Data are represented as the mean ± SEM (n = 8). Significantly different from the vehicle group by Dunnett’s test at **P < 0.005 (one tailed). Vehicle: dimethyl sulfoxide (DMSO)/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + 0.05% Tween80 PBS [s.c.], LY3502970: LY3502970 [p.o.] + 0.05% Tween 80 PBS [s.c.], exenatide: DMSO/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + exenatide [s.c.].
Fig. 5. LY3502970 enhances glucose-stimulated insulin secretion and reduces food consumption in cynomolgus monkeys. (B–E) Effects of LY3502970 in IVGTT experiments. (A) Schematic diagram of the IVGTT procedure in anesthetized cynomolgus monkeys. Dosing of LY3502970 or exenatide was performed by manual bolus injection, followed by continuous infusion for 80 min. Forty minutes after initiating dosing of vehicle or the drug, glucose was administered intravenously. (B and C) Effect of LY3502970 (B) or exenatide (C) on blood glucose levels. (D and E) Effect of LY3502970 (D) or exenatide (E) on serum insulin levels. Data are represented as the mean ± SEM (n = 7). Significantly different from vehicle 1 or vehicle 2 by Dunnett’s test at *P < 0.025 and **P < 0.005 (one tailed), respectively. Vehicle 1: PEG400/PG/Gly NaOH buffer (pH 9), vehicle 2: 0.05% Tween80 PBS. (F and G) Mean food consumption following administration of LY3502970 (F) or exenatide (G). Cynomolgus monkeys were administered LY3502970, exenatide, or vehicle once daily for 5 d with a 2 d recovery period using an 8 × 5 cross-over design. Food consumption during the 90 min period after feeding was measured. Data are represented as the mean ± SEM (n = 8). Significantly different from the vehicle group by Dunnett’s test at **P < 0.005 (one tailed). Vehicle: dimethyl sulfoxide (DMSO)/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + 0.05% Tween80 PBS [s.c.], LY3502970: LY3502970 [p.o.] + 0.05% Tween 80 PBS [s.c.], exenatide: DMSO/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + exenatide [s.c.].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. T. Nguyen, Drug structures displayed for the first time in Orlando. Chem. Eng. News (2019).

Cited by

See all 231

Metadata

Authors
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W.
Affiliations
  • Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
  • ConfometRx (United States) (US)
  • Eli Lilly (United States) (US)
Corresponding author
  • Suzuki, Yoshiyuki
  • Kobilka, Brian K.
  • Sloop, Kyle W.
Venue
Proceedings of the National Academy of Sciences
Published
2020-11-11
Volume
117
Issue
47
Pages
29959-29967
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3099724881
Cited by
231
References
51
Citations by year
2026: 68 · 2025: 53 · 2024: 44 · 2023: 30 · 2022: 19 · 2021: 15 · 2020: 2
FWCI
5.51
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
GLP-1 receptor, class B G protein-coupled receptors, receptor structure, partial agonism, biased signaling, G protein activation, beta-arrestin, oral antidiabetic drugs, type 2 diabetes, insulin secretion, blood glucose reduction, non-human primates
MeSH terms
Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Aminopyridines, Animals, Benzamides, Humans, Hypoglycemic Agents, Macaca fascicularis, Male, Mice, Transgenic, Models, Molecular, Species Specificity, Swine, Tryptophan, Mutagenesis, Site-Directed, Anti-Obesity Agents, Cryoelectron Microscopy, Mice, Rats, Incretins, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. https://app.cochat.ai/papers/10.1073/pnas.2014879117
The paper
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W. (2020). Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2014879117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.